Wolverine Trading’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $603K | Buy |
46,700
+16,800
| +56% | +$224K | ﹤0.01% | 3477 |
|
|
2025
Q2 | $538K | Buy |
29,900
+7,200
| +32% | +$125K | ﹤0.01% | 2881 |
|
|
2025
Q1 | $428K | Sell |
22,700
-10,500
| -32% | -$238K | ﹤0.01% | 3148 |
|
|
2024
Q4 | $999K | Buy |
33,200
+6,500
| +24% | +$138K | ﹤0.01% | 2656 |
|
|
2024
Q3 | $417K | Sell |
26,700
-12,700
| -32% | -$230K | ﹤0.01% | 3251 |
|
|
2024
Q2 | $675K | Buy |
39,400
+9,400
| +31% | +$165K | ﹤0.01% | 2554 |
|
|
2024
Q1 | $469K | Buy |
30,000
+1,700
| +6% | +$25K | ﹤0.01% | 2907 |
|
|
2023
Q4 | $423K | Sell |
28,300
-12,400
| -30% | -$166K | ﹤0.01% | 3130 |
|
|
2023
Q3 | $657K | Buy |
40,700
+1,600
| +4% | +$46.1K | ﹤0.01% | 2504 |
|
|
2023
Q2 | $1.58M | Buy |
39,100
+17,900
| +84% | +$1.11M | ﹤0.01% | 1645 |
|
|
2023
Q1 | $1.24M | Sell |
21,200
-19,600
| -48% | -$1.57M | ﹤0.01% | 1729 |
|
|
2022
Q4 | $2.99M | Buy |
40,800
+8,900
| +28% | +$670K | ﹤0.01% | 1155 |
|
|
2022
Q3 | $2.46M | Buy |
31,900
+2,300
| +8% | +$179K | ﹤0.01% | 1259 |
|
|
2022
Q2 | $2.14M | Buy |
29,600
+2,600
| +10% | +$196K | ﹤0.01% | 1327 |
|
|
2022
Q1 | $2.27M | Sell |
27,000
-43,000
| -61% | -$3.17M | ﹤0.01% | 1650 |
|
|
2021
Q4 | $5.59M | Sell |
70,000
-6,300
| -8% | -$632K | 0.01% | 1085 |
|
|
2021
Q3 | $8.86M | Buy |
76,300
+8,000
| +12% | +$1.21M | 0.01% | 887 |
|
|
2021
Q2 | $15.3M | Sell |
68,300
-42,800
| -39% | -$8.33M | 0.02% | 518 |
|
|
2021
Q1 | $13.9M | Buy |
+111,100
| New | +$17.6M | 0.02% | 537 |
|
|
2020
Q4 | – | Sell |
-153,800
| Closed | -$16.8M | – | 5256 |
|
|
2020
Q3 | $16.8M | Buy |
153,800
+78,500
| +104% | +$6.28M | 0.04% | 353 |
|
|
2020
Q2 | $4.34M | Sell |
75,300
-84,000
| -53% | -$5.52M | 0.01% | 890 |
|
|
2020
Q1 | $11.2M | Sell |
159,300
-39,600
| -20% | -$3.13M | 0.03% | 390 |
|
|
2019
Q4 | $17M | Sell |
198,900
-94,200
| -32% | -$7.6M | 0.04% | 431 |
|
|
2019
Q3 | $21.5M | Buy |
293,100
+196,200
| +202% | +$15.7M | 0.06% | 257 |
|
|
2019
Q2 | $6.13M | Buy |
+96,900
| New | +$4.91M | 0.02% | 767 |
|
|
2019
Q1 | – | Sell |
-81,000
| Closed | -$2.66M | – | 5055 |
|
|
2018
Q4 | $2.66M | Sell |
81,000
-95,500
| -54% | -$3.49M | 0.01% | 1208 |
|
|
2018
Q3 | $9.25M | Buy |
176,500
+112,500
| +176% | +$4.48M | 0.02% | 602 |
|
|
2018
Q2 | $1.4M | Hold |
64,000
| – | – | ﹤0.01% | 1907 |
|
|
2018
Q1 | $1.4M | Sell |
64,000
-15,600
| -20% | -$336K | ﹤0.01% | 1907 |
|
|
2017
Q4 | $1.61M | Buy |
+79,600
| New | +$1.53M | 0.01% | 1726 |
|
|
2017
Q3 | – | Sell |
-74,000
| Closed | -$1.27M | – | 4826 |
|
|
2017
Q2 | $1.27M | Buy |
+74,000
| New | +$955K | 0.01% | 1551 |
|
|
2017
Q1 | – | Sell |
-44,900
| Closed | -$352K | – | 4770 |
|
|
2016
Q4 | $352K | Buy |
44,900
+23,500
| +110% | +$189K | ﹤0.01% | 3061 |
|
|
2016
Q3 | $183K | Buy |
+21,400
| New | +$195K | ﹤0.01% | 3892 |
|
Other funds holding NVCR
SCM
N
QCM
Wolverine Trading's NVCR Position: Q1 2025 in Review
Wolverine Trading sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 9,799 shares — an estimated $223K sold.
Wolverine Trading first reported a position in NVCR in Q2 2016 and held it in 20 quarters. The position peaked at $4.48M in Q2 2021. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.
- Wolverine Trading reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
- Wolverine Trading sold 9,799 NovoCure shares in Q1 2025, an estimated $223K.
- Wolverine Trading first reported a position in NovoCure in Q2 2016 and held it in 20 quarters.
- Wolverine Trading's NovoCure position peaked at $4.48M in Q2 2021.
- 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.
Based on Wolverine Trading's 13F filing for Q1 2025, filed 15 May 2025.